

## Targeting of histamine producing cells by EGCG: a green dart against inflammation?

Esther Melgarejo · Miguel Ángel Medina ·  
Francisca Sánchez-Jiménez · José Luis Urdiales

Received: 14 April 2010 / Accepted: 30 June 2010 / Published online: 22 July 2010  
© University of Navarra 2010

**Abstract** The human body is made of some 250 different cell types. From them, only a small subset of cell types is able to produce histamine. They include some neurons, enterochromaffin-like cells, gastrin-containing cells, mast cells, basophils, and monocytes/macrophages, among others. In spite of the reduced number of these histamine-producing cell types, they are involved in very different physiological processes. Their deregulation is related with many highly prevalent, as well as emergent and rare diseases, mainly those described as inflammation-dependent pathologies, including mastocytosis, basophilic leukemia, gastric ulcer, Crohn disease, and other inflammatory bowel diseases. Furthermore, oncogenic transformation switches some non-histamine-producing cells to a histamine producing phenotype. This is the case of melanoma, small cell lung carcinoma, and several types of neuroendocrine tumors. The bioactive compound epigallocatechin-3-gallate (EGCG), a major component of green tea, has been shown to target histamine-producing cells producing

great alterations in their behavior, with relevant effects on their proliferative potential, as well as their adhesion, migration, and invasion potentials. In fact, EGCG has been shown to have potent anti-inflammatory, anti-tumoral, and anti-angiogenic effects and to be a potent inhibitor of the histamine-producing enzyme, histidine decarboxylase. Herein, we review the many specific effects of EGCG on concrete molecular targets of histamine-producing cells and discuss the relevance of these data to support the potential therapeutic interest of this compound to treat inflammation-dependent diseases.

**Keywords** EGCG · Histamine-producing cells · Inflammation

### Introduction

Inflammation is the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. It is a protective attempt by the organism to remove the injurious stimuli as well as to initiate the healing process for the tissue. Inflammation is normally tightly regulated by interaction between mediators of inflammation and inflammatory cells and errors in the system cause many complex diseases (e.g., sepsis, infectious diseases, trauma, asthma, allergy, autoimmune disorders, transplant rejection, cancer, neurodegenerative diseases, obesity, and atherosclerosis) [57].

---

E. Melgarejo · M. Á. Medina · F. Sánchez-Jiménez  
Departamento de Biología Molecular y Bioquímica,  
Facultad de Ciencias, Universidad de Málaga and CIBER  
de Enfermedades Raras (CIBERER),  
29071 Málaga, Spain

J. L. Urdiales (✉)  
Departamento de Biología Molecular y Bioquímica,  
Facultad de Ciencias, Universidad de Málaga and CIBER  
de Enfermedades Raras (CIBERER),  
29071 Málaga, Spain  
e-mail: jlurdial@uma.es

Cytokines represent a group of small polypeptides involved in many steps of the inflammatory response. They form a complex and redundant network with pleiotropic activity and functional redundancy [22]. Cytokines are produced by both resident and migrating cells, such as mast cells, macrophages, and neutrophils, and after release, they can act either locally or systemically.

### Green tea composition

Tea is the second beverage most consumed in the world after water. It is a product made up from leaves and buds of *Camellia sinensis*. There are different types of tea depending on manufacturing process: white tea is the uncured and unfermented tea leaf, green tea is “non-fermented,” oolong tea is “semi-fermented,” and black or red tea is “post-harvested fermented” before drying and steaming. Tea consumption is part of many people daily routine, as an everyday drink and as a therapeutic aid in many illnesses. Chinese have known about the medicinal benefits of green tea since ancient times, using it for treatment of headaches, body aches and pains, digestion, depression, detoxification, as an energizer and, in general, to prolong life. In recent years, the legendary medicinal properties of tea have been given serious scientific support.

Tea is a natural source of the amino acid theanine, methylxanthines such as caffeine and theobromine, and polyphenolic antioxidant. Polyphenols constitute the most interesting group of green tea components and green tea can be considered an important source of polyphenols, particularly flavonoids. The main flavonoids present in green tea are catechins (flavans-3-ols). There are four major catechins: (–)-epigallocatechin-3-gallate (EGCG; approximately 59% of total catechins), (–)-epigallocatechin (EGC; 19% approximately), (–)-epicatechin-3-gallate (ECG, 13.6% approximately), and (–)-epicatechin (EC; 6.4% approximately) [10].

### Properties of green tea in human health

In vitro and animal studies provide strong evidence that green tea polyphenols may play a role in the risk and pathogenesis of several chronic diseases, especially cardiovascular disease and cancer, and related patholo-

gies. In addition, several studies suggest a beneficial impact of green tea intake on bone density, cognitive function, dental caries, and kidney stones, among other effects [45, 64]. Over the last years, numerous epidemiological and clinical studies have revealed several physiological responses to green tea which may be relevant to the promotion of health and the prevention or treatment of some chronic diseases [27, 38]. It has biological and pharmacological properties such as anticarcinogenic, antimetastatic, antioxidative, antihypertensive, and anti-hypercholesterolemic activities [8, 11, 13, 24, 34, 42, 58, 59]. Major principles for these activities were shown to be catechins. These polyphenols are antioxidant in nature and have been shown to function as anti-inflammatory and anticarcinogenic agents in various biological systems [29, 63]. EGCG, the most abundant polyphenol in green tea leaves, is believed to be the most responsible compound for the health benefits attributed to tea [20].

Several studies showed that EGCG induces apoptosis and cell cycle arrest in tumor cells [21, 56], inhibits urokinase activity [28], matrix metalloproteinases, and urokinase-plasminogen activator [23], cell proliferation [4, 32], lipooxygenase, and cyclooxygenase activities [25, 54], and the expression of angiogenesis related genes [47].

### Modulation of inflammation pathways by EGCG

Several studies demonstrate that EGCG can modulate multiple signal transduction pathways in a way that suppresses the expression of inflammation mediators.

- Effect of EGCG on nuclear factor-kappa B (NF- $\kappa$ B) signaling pathway. EGCG inhibits NF- $\kappa$ B activity by blocking the phosphorylation of I $\kappa$ B- $\alpha$  [1, 40, 60]. This inhibition results in the decrease in the expression of inflammatory genes products including lipooxygenase [66], cyclooxygenase [37], NO synthase [12], and TNF- $\alpha$  [67].
- Effects of EGCG on mitogen activated protein kinases (MAPKs) and activator protein-1 (AP-1) pathways. EGCG exerted a marked inhibition of both basal and IL-1-stimulated MAPKs phosphorylation [6] and suppressed the RANKL-induced activation of JNK pathway [36]. EGCG was also found to inhibit the DNA binding activity of AP-1 in human chondrocytes [6].

- Effects of EGCG on signal transducers and activators of transcription (STAT) pathway. EGCG exert a potent and specific inhibitory effect on STAT1 activation in a number of human cell types [49, 62]. Moreover, it was reported that EGCG can suppress STAT-3 phosphorylation in human gingival [26] and fibroblasts [53].
- Effects of EGCG on inflammatory cytokines and chemokines expression. EGCG has been shown to inhibit the TNF- $\alpha$  gene expression and its secretion in different cell types [14]. EGCG has also been shown to downregulate IL-1 $\beta$ -induced RANTES and GRO- $\alpha$  production in human fibroblast [2] and MCP-1 expression in fibroblasts [2], monocytes, and macrophages [47, 48].
- Antioxidant effects of EGCG. Investigations from a number of laboratories have demonstrated that green tea polyphenols are efficient free radical and singlet oxygen scavengers [33]. EGCG also considerably increased the gene expressions of catalase, superoxide dismutase, and glutathione peroxidase activities which are essential components of a robust antioxidant defense system [50].
- Induction of apoptosis and cell cycle arrest by EGCG. EGCG has been shown to affect a number of factors associated with cell cycle progression, but the direct inhibition of cyclin-dependent kinases is considered the primary event. This inhibition could be the consequence of the induction of various negative regulators of the cell cycle. EGCG also induces the expression of p21 and p27 while decreasing the expression of cyclin D<sub>1</sub> and the phosphorylation of retinoblastoma [35].

### Effects of EGCG on histamine handling cells

Histamine is a biogenic amine with a major role in different physiological function such the contraction of smooth muscles, increase in vascular permeability, stimulation of gastric acid secretion, neurotransmission, immunomodulation, proliferation, etc [7, 9]. Among all the cell types of the human body, only a small subset of cell types is able to produce histamine. They include some neurons, enterochromaffin-like cells, gastrin containing cells, mast cells, basophils, and monocytes/macrophages, among others. Herein,

we briefly summarize what is currently known concerning molecular targets of EGCG in these histamine handling cells.

#### Cells from the immune/inflammatory axis

Besides studies on cancer cells, the most abundant and extensive studies of EGCG effects on molecular targets have been carried out with cells from the immune/inflammatory axis.

- Megakaryocytes. EGCG has been shown to increase megakaryocyte and platelet numbers in cultures supplemented with thrombopoietin, a central regulator of megakaryocytopoiesis and platelet production. Furthermore, EGCG also exerts a clear radio-protective effect on this cell lineage [51].
- Monocytes/macrophages. It has been shown that EGCG is capable of modulating radical oxygen species production during respiratory burst of rat macrophages. In this and other cases, EGCG acts as an effective superoxide anion scavenger [5]. An indirect effect of EGCG on monocyte/macrophage physiology is the inhibitory effect caused on endothelial VCAM-1, which is accompanied by a decreased monocyte adhesion to endothelial cells [41]. On the other hand, EGCG specifically promotes monocyte apoptosis [30]. Recently, EGCG has been shown to inhibit the late pro-inflammatory cytokine HMGB1 (high mobility group box 1) release by monocytes/macrophages upon stimulation of bacterial endotoxin. This, in turn, gives rise to a rescue of mice from lethal sepsis [39]. Furthermore, EGCG has also been shown to inhibit intracellular survival of pathogenic bacteria within macrophages [31]. More recently, our group has been shown that treatment of THP-1 cells with EGCG decreased MCP-1 and CCR2 gene expression, together with MCP-1 secretion and CCR2 expression at the cell surface. EGCG also inhibited beta1 integrin activation. The effects on these molecular targets were in agreement with the EGCG-induced inhibition of THP-1 migration in response to MCP-1 and adhesion to fibronectin [48].
- Basophilic cells. A well-known direct molecular target of EGCG is the high-affinity IgE receptor Fc $\epsilon$ RI. In fact, Fc $\epsilon$ RI expression in basophilic cells is suppressed by EGCG [15, 16]. More recently, the 67-kDa laminin receptor has been shown as another

direct molecular target for EGCG and a determinant of its degranulation inhibitory and anti-allergic effects [17–19]. Very interestingly, this 67-kDa laminin receptor is metastasis-associated and confers EGCG responsiveness to cancer cells at physiologically relevant concentrations [61].

- Mast cells. Histamine is a key mediator of allergic and inflammatory responses. This biogenic amine is produced in a reaction catalyzed by histidine decarboxylase (HDC) [46]. EGCG targets histamine at two levels. On the one hand, EGCG has been shown to inhibit mast cell degranulation [65]. On the other hand, our group firstly demonstrated a potent inhibitory effect of EGCG on HDC activity [55]. Very recently, our results have been confirmed by an independent study showing that, in fact, among 22 tested food components, EGCG (along with epicatechin gallate) was the most effective inhibitor of HDC [52]. On the other hand, another recent study carried out by our group has shown that, among others, EGCG reduces the expression of the integrins  $\alpha 5$  and  $\beta 3$ , as well as that of the chemokine MCP1 (monocyte chemo-attractant protein 1), giving rise to a lower adhesion and migration of mast cells, associated with a decreased potential to produce signals eliciting monocyte recruitment [47].

#### Neurons and other histamine-handling cells

For histamine-handling neurons, EGCG has been shown to exert multifunctional effects, including neuroprotection, metal-chelatin-radical scavenging, and anti-inflammation [3, 43, 44].

Neuroendocrine cells secreting gastrin and/or biogenic amines in the stomach are most probably cellular targets for the action of EGCG. However, this research topic remains to be studied, with the exception of some articles describing the protective effect of EGCG against *Helicobacter pylori*-induced gastric epithelial cytotoxicity and the inhibitory effect of EGCG against gastric cancer cell proliferation and angiogenesis [68].

#### Pathobiological relevance

There is increasing evidence pointing to the beneficial anti-inflammatory effects of EGCG. They include its

neuroprotective and radio-protective actions, its potent inhibitory effect on cytokine and chemokine release, its molecular targets leading to monocyte apoptosis, mast cell degranulation inhibition, HDC activity inhibition, as well as its interference with mast cell adhesiveness, migration, and monocyte recruitment. All these effects point to EGCG as a very promising anti-inflammatory agent with potential pharmacological interest to be evaluated in clinical trials. However, further in-depth mechanistic studies in vitro and appropriate and relevant animal model studies in vivo are needed together in order to fully appreciate the value of EGCG in inflammation and other aspects of human health and diseases in the future.

**Acknowledgements** The experimental work carried out by our group is supported by grants SAF 2005-01812 and PS09/02216 (Spanish Ministry of Science and Innovation), Fundación Ramón Areces, P07-CVI-02999 and group BIO-267 (Andalusian Government). The “CIBER de Enfermedades Raras” is an initiative of the ISCIII (Spain).

#### References

1. Ahmad N, Gupta S, Mukhtar H (2000) Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. *Arch Biochem Biophys* 376:338–346
2. Ahmed S, Pakozdi A, Koch AE (2006) Regulation of interleukin-1beta-induced chemokine production and matrix metalloproteinase 2 activation by epigallocatechin-3-gallate in rheumatoid arthritis synovial fibroblasts. *Arthritis Rheum* 54:2393–2401
3. Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F (2004) Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. *J Immunol* 173:5794–5800
4. Albrecht DS, Clubbs EA, Ferruzzi M, Bomser JA (2008) Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. *Chem Biol Interact* 171:89–95
5. Alvarez E, Leiro J, Orallo F (2002) Effect of (-)-epigallocatechin-3-gallate on respiratory burst of rat macrophages. *Int Immunopharmacol* 2:849–855
6. Andriamanalijaona R, Kypriotou M, Bauge C, Renard E, Legendre F, Raoudi M, Boumediene K, Gatto H, Monginoux P, Pujol JP (2005) Comparative effects of 2 antioxidants, selenomethionine and epigallocatechin-gallate, on catabolic and anabolic gene expression of articular chondrocytes. *J Rheumatol* 32:1958–1967
7. Beaven M (1978) Histamine: its role in physiological and pathological process. *Monogr Allergy* 13:1–113

8. Bors W, Saran M (1987) Radical scavenging by flavonoid antioxidants. *Free Radic Res Commun* 2:289–294
9. Brown NJ, Roberts II (2001) Histamine, bradykinin, and their antagonists. In: Hardman JG, Limbird LE, Gilman AG (eds) *The Pharmaceutical Basis of Therapeutics*, 10th edn. McGraw Hill, New York, pp 645–668
10. Cabrera C, Artacho R, Gimenez R (2006) Beneficial effects of green tea—a review. *J Am Coll Nutr* 25:79–99
11. Cao Y, Cao R (1999) Angiogenesis inhibited by drinking tea. *Nature* 398:381
12. Chan MM, Fong D, Ho CT, Huang HI (1997) Inhibition of inducible nitric oxide synthase gene expression and enzyme activity by epigallocatechin gallate, a natural product from green tea. *Biochem Pharmacol* 54:1281–1286
13. Chisaka T, Matsuda H, Kubomura Y, Mochizuki M, Yamahara J, Fujimura H (1988) The effect of crude drugs on experimental hypercholesteremia: mode of action of (-)-epigallocatechin gallate in tea leaves. *Chem Pharm Bull (Tokyo)* 36:227–233
14. Fujiki H, Suganuma M, Kurusu M, Okabe S, Imayoshi Y, Taniguchi S, Yoshida T (2003) New TNF- $\alpha$  releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. *Mutat Res* 523–524:119–125
15. Fujimura Y, Tachibana H, Yamada K (2001) A tea catechin suppresses the expression of the high-affinity IgE receptor Fc epsilon RI in human basophilic KU812 cells. *J Agric Food Chem* 49:2527–2531
16. Fujimura Y, Tachibana H, Maeda-Yamamoto M, Miyase T, Sano M, Yamada K (2002) Antiallergic tea catechin, (-)-epigallocatechin-3-O-(3-O-methyl)-gallate, suppresses FcepsilonRI expression in human basophilic KU812 cells. *J Agric Food Chem* 50:5729–5734
17. Fujimura Y, Umeda D, Kiyohara Y, Sunada Y, Yamada K, Tachibana H (2006) The involvement of the 67 kDa laminin receptor-mediated modulation of cytoskeleton in the degranulation inhibition induced by epigallocatechin-3-O-gallate. *Biochem Biophys Res Commun* 348:524–531
18. Fujimura Y, Umeda D, Yano S, Maeda-Yamamoto M, Yamada K, Tachibana H (2007) The 67 kDa laminin receptor as a primary determinant of anti-allergic effects of O-methylated EGCG. *Biochem Biophys Res Commun* 364:79–85
19. Fujimura Y, Umeda D, Yamada K, Tachibana H (2008) The impact of the 67 kDa laminin receptor on both cell-surface binding and anti-allergic action of tea catechins. *Arch Biochem Biophys* 476:133–138
20. Graham HN (1992) Green tea composition, consumption, and polyphenol chemistry. *Prev Med* 21:334–350
21. Gupta S, Hussain T, Mukhtar H (2003) Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. *Arch Biochem Biophys* 410:177–185
22. Haddad JJ (2002) Cytokines and related receptor-mediated signaling pathways. *Biochem Biophys Res Commun* 297:700–713
23. Ho YC, Yang SF, Peng CY, Chou MY, Chang YC (2007) Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator. *J Oral Pathol Med* 36:588–593
24. Hodgson JM, Puddey IB, Burke V, Beilin LJ, Jordan N (1999) Effects on blood pressure of drinking green and black tea. *J Hypertens* 17:457–463
25. Hong J, Smith TJ, Ho CT, August DA, Yang CS (2001) Effects of purified green and black tea polyphenols on cyclooxygenase- and lipoxygenase-dependent metabolism of arachidonic acid in human colon mucosa and colon tumor tissues. *Biochem Pharmacol* 62:1175–1183
26. Hosokawa Y, Hosokawa I, Ozaki K, Nakanishi T, Nakae H, Matsuo T (2010) Catechins inhibit CXCL10 production from oncostatin M-stimulated human gingival fibroblasts. *J Nutr Biochem* 21(7):659–664
27. Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Kuroishi T, Tominaga S (1998) Tea and coffee consumption and the risk of digestive tract cancers: data from a comparative case-referent study in Japan. *Cancer Causes Control* 9:209–216
28. Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E (1997) Why drinking green tea could prevent cancer. *Nature* 387:561
29. Katiyar SK, Mukhtar H (1997) Tea antioxidants in cancer chemoprevention. *J Cell Biochem Suppl* 27:59–67
30. Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, Sasaki S, Watanabe T, Takahashi K, Nagawa H (2005) Epigallocatechin gallate induces apoptosis of monocytes. *J Allergy Clin Immunol* 115:186–191
31. Kohda C, Yanagawa Y, Shimamura T (2008) Epigallocatechin gallate inhibits intracellular survival of *Listeria monocytogenes* in macrophages. *Biochem Biophys Res Commun* 365:310–315
32. Kuo PL, Lin CC (2003) Green tea constituent (-)-epigallocatechin-3-gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. *J Biomed Sci* 10:219–227
33. Kurien BT, Hensley K, Bachmann M, Scofield RH (2006) Oxidatively modified autoantigens in autoimmune diseases. *Free Radic Biol Med* 41:549–556
34. Lambert JD, Yang CS (2003) Cancer chemopreventive activity and bioavailability of tea and tea polyphenols. *Mutat Res* 523–524:201–208
35. Lambert JD, Hong J, Yang GY, Liao J, Yang CS (2005) Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. *Am J Clin Nutr* 81:284S–291S
36. Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH (2010) Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. *Mol Pharmacol* 77:17–25
37. Lee S, Simon MD (1999) Role and regulation of cyclooxygenase-2 during inflammation. *Am J Med* 106:37S–42S
38. Lee IP, Kim YH, Kang MH, Roberts C, Shim JS, Roh JK (1997) Chemopreventive effect of green tea (*Camellia sinensis*) against cigarette smoke-induced mutations (SCE) in humans. *J Cell Biochem Suppl* 27:68–75
39. Li W, Ashok M, Li J, Yang H, Sama AE, Wang H (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. *PLoS ONE* 2:e1153
40. Lin RW, Chen CH, Wang YH, Ho ML, Hung SH, Chen IS, Wang GJ (2009) (-)-Epigallocatechin gallate inhibition of osteoclastic differentiation via NF-kappaB. *Biochem Biophys Res Commun* 379:1033–1037

41. Ludwig A, Lorenz M, Grimbo N, Steinle F, Meiners S, Bartsch C, Stangl K, Baumann G, Stangl V (2004) The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. *Biochem Biophys Res Commun* 316:659–665
42. Maeda-Yamamoto M, Suzuki N, Sawai Y, Miyase T, Sano M, Hashimoto-Ohta A, Isemura M (2003) Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells. *J Agric Food Chem* 51:1858–1863
43. Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, Youdim MB (2005) Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. *NeuroSignals* 14:46–60
44. Mandel S, Amit T, Bar-Am O, Youdim MB (2007) Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. *Prog Neurobiol* 82:348–360
45. McKay DL, Blumberg JB (2002) The role of tea in human health: an update. *J Am Coll Nutr* 21:1–13
46. Medina MA, Urdiales JL, Rodriguez-Caso C, Ramirez FJ, Sanchez-Jimenez F (2003) Biogenic amines and polyamines: similar biochemistry for different physiological missions and biomedical applications. *Crit Rev Biochem Mol Biol* 38:23–59
47. Melgarejo E, Medina MA, Sanchez-Jimenez F, Botana LM, Dominguez M, Escribano L, Orfao A, Urdiales JL (2007) (-)-Epigallocatechin-3-gallate interferes with mast cell adhesiveness, migration and its potential to recruit monocytes. *Cell Mol Life Sci* 64:2690–2701
48. Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL (2009) Epigallocatechin gallate reduces human monocyte mobility and adhesion in vitro. *Br J Pharmacol* 158:1705–1712
49. Menegazzi M, Tedeschi E, Dussin D, De Prati AC, Cavalieri E, Mariotto S, Suzuki H (2001) Anti-interferon gamma action of epigallocatechin-3-gallate mediated by specific inhibition of STAT1 activation. *FASEB J* 15:1309–1311
50. Meng Q, Velalar CN, Ruan R (2008) Effects of epigallocatechin-3-gallate on mitochondrial integrity and antioxidative enzyme activity in the aging process of human fibroblast. *Free Radic Biol Med* 44:1032–1041
51. Monzen S, Mori T, Takahashi K, Abe Y, Inanami O, Kuwabara M, Kashiwakura I (2006) The effects of (-)-epigallocatechin-3-gallate on the proliferation and differentiation of human megakaryocytic progenitor cells. *J Radiat Res (Tokyo)* 47:213–220
52. Nitta Y, Kikuzaki H, Ueno H (2007) Food components inhibiting recombinant human histidine decarboxylase activity. *J Agric Food Chem* 55:299–304
53. Park G, Yoon BS, Moon JH, Kim B, Jun EK, Oh S, Kim H, Song HJ, Noh JY, Oh C, You S (2008) Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. *J Invest Dermatol* 128:2429–2441
54. Peng G, Dixon DA, Muga SJ, Smith TJ, Wargovich MJ (2006) Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. *Mol Carcinog* 45:309–319
55. Rodriguez-Caso C, Rodriguez-Agudo D, Sanchez-Jimenez F, Medina MA (2003) Green tea epigallocatechin-3-gallate is an inhibitor of mammalian histidine decarboxylase. *Cell Mol Life Sci* 60:1760–1763
56. Roy AM, Baliga MS, Katiyar SK (2005) Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. *Mol Cancer Ther* 4:81–90
57. Sacca R, Cuff CA, Ruddle NH (1997) Mediators of inflammation. *Curr Opin Immunol* 9:851–857
58. Sano M, Takahashi Y, Yoshino K, Shimoi K, Nakamura Y, Tomita I, Oguni I, Konomoto H (1995) Effect of tea (*Camellia sinensis* L.) on lipid peroxidation in rat liver and kidney: a comparison of green and black tea feeding. *Biol Pharm Bull* 18:1006–1008
59. Sazuka M, Murakami S, Isemura M, Satoh K, Nukiwa T (1995) Inhibitory effects of green tea infusion on in vitro invasion and in vivo metastasis of mouse lung carcinoma cells. *Cancer Lett* 98:27–31
60. Singh R, Ahmed S, Islam N, Goldberg VM, Haqqi TM (2002) Epigallocatechin-3-gallate inhibits interleukin-1 $\beta$ -induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor kappaB activation by degradation of the inhibitor of nuclear factor kappaB. *Arthritis Rheum* 46:2079–2086
61. Tachibana H, Koga K, Fujimura Y, Yamada K (2004) A receptor for green tea polyphenol EGCG. *Nat Struct Mol Biol* 11:380–381
62. Tedeschi E, Suzuki H, Menegazzi M (2002) Antiinflammatory action of EGCG, the main component of green tea, through STAT-1 inhibition. *Ann NY Acad Sci* 973:435–437
63. Tipoe GL, Leung TM, Hung MW, Fung ML (2007) Green tea polyphenols as an anti-oxidant and anti-inflammatory agent for cardiovascular protection. *Cardiovasc Hematol Disord Drug Targets* 7:135–144
64. Wu CD, Wei GX (2002) Tea as a functional food for oral health. *Nutrition* 18:443–444
65. Yamashita K, Suzuki Y, Matsui T, Yoshimaru T, Yamaki M, Suzuki-Karasaki M, Hayakawa S, Shimizu K (2000) Epigallocatechin gallate inhibits histamine release from rat basophilic leukemia (RBL-2H3) cells: role of tyrosine phosphorylation pathway. *Biochem Biophys Res Commun* 274:603–608
66. Yang TT, Koo MW (2000) Inhibitory effect of Chinese green tea on endothelial cell-induced LDL oxidation. *Atherosclerosis* 148:67–73
67. Yang F, de Villiers WJ, McClain CJ, Varilek GW (1998) Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. *J Nutr* 128:2334–2340
68. Zhu BH, Zhan WH, Li ZR, Wang Z, He YL, Peng JS, Cai SR, Ma JP, Zhang CH (2007) (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. *World J Gastroenterol* 13:1162–1169